Close Menu

NEW YORK – Cardea Bio said on Tuesday that it has raised $6.5 million in an extension of its Series A financing round, bringing the total the company has raised in this Series A round to more than $20 million.

The new capital infusion was led by the life sciences and biotechnology focused investor 3E Bioventures Capital and was joined by existing investors. Cardea will use the proceeds to further develop its Transistor platform, significantly expand mass manufacturing, and further grow its commercial partnerships.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.